title: [Value of antidiuretic, anticholinergic, and anti-inflammatory drugs and botulinum toxin for the treatment of voiding disorders related to BPH (CTMH-AFU forum 2005)].
abstract: New therapeutic approaches have recently been investigated in order to improve the voiding disorders of patient with lower urinary tract symptoms related to benign prostatic hyperplasia. The purpose of this article is to provide a review of these treatments: anti-inflammatory, antidiuretic, anticholinergic and botulinum toxin. Anticholinergic drugs associated with a risk of urinary retention, appear to be effective for irritative disorders in combination with an alpha-blocker. Antidiuretics can be proposed in patients younger than 65 with disabling polyuria confirmed by a voiding diary, related to BPH and refractory to conventional treatment of BPH. The interaction between inflammation and BPH has not yet been clarified, but anti-inflammatory drugs appear to improve symptoms and may have a place in short-term treatment of BPH, as their long-term use is not recommended and COX-2 inhibitors have been withdrawn from the market. Finally, botulinum toxin could have a place in the treatment of disorders related to BPH if clinical studies confirm the recently published promising results. These new approaches will probably be integrated into guidelines and flow-charts for the treatment of voiding disorders related to BPH.
authors.affiliation: Service Urologie, CHU Mondor, Créteil, France. adelataille@hotmail.com
authors.forename: Alexandre
authors.initials: A
authors.lastname: De la Taille
authors.forename: Marc
authors.initials: M
authors.lastname: Fourmarier
authors.forename: Francois
authors.initials: F
authors.lastname: Desgrandchamps
authors.forename: Charles
authors.initials: C
authors.lastname: Ballereau
authors.forename: Christian
authors.initials: C
authors.lastname: Saussine
authors.forename: Olivier
authors.initials: O
authors.lastname: Haillot
authors.forename: Abdel-Rahmène
authors.initials: AR
authors.lastname: Azzouzi
authors.forename: Bertrand
authors.initials: B
authors.lastname: Lukacs
authors.forename: Marian
authors.initials: M
authors.lastname: Devonec
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D050034:Antidiuretic Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications*; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000893:Anti-Inflammatory Agents; D050034:Antidiuretic Agents; D018680:Cholinergic Antagonists; D001905:Botulinum Toxins